Eliquis fails to beat Lovenox at clot-fighting after surgery

In a study that could give versions of Sanofi's Lovenox a boost, the new Bristol-Myers Squibb ($BMY) and Pfizer ($PFE) anti-coagulant Eliquis failed to prove superior to the older drug in preventing clots after surgery. The ADOPT trial showed Lovenox staved off venous thromboembolism and VTE-related death in all but 3.1% of patients, while Eliquis prevented VTE and VTE death in all but 2.7%. Lovenox's lone generic competitor comes from Momenta Pharmaceuticals ($MNTA) and Sandoz, while another is waiting in the wings. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.